The Lancet Oncology

The Lancet Oncology
Enasidenib Plus Azacitidine versus Azacitidine Alone in Patients With Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukaemia (AG221-AML-005)

This study evaluated the safety and activity of enasidenib plus azacitidine vs azacitidine alone in patients with newly diagnosed, mutant-IDH2 AML ineligible for intensive chemotherapy.

The Lancet Oncology
Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone Alone in Newly Diagnosed Multiple Myeloma

A significant improvement in progression-free survival was observed with daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone...

The Lancet Oncology
Apalutamide plus Abiraterone Acetate and Prednisone versus Placebo Plus Abiraterone and Prednisone in Metastatic, Castration-Resistant Prostate Cancer

Scientists investigate the combination treatment using apalutamide plus abiraterone acetate, each of which suppresses the androgen signalling axis in a different way, versus standard care in mCRPC.

The Lancet Oncology
Lenvatinib With Etoposide Plus Ifosfamide in Patients With R/R Osteosarcoma

Investigators determine the recommended phase 2 dose and antitumour activity of lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma.

The Lancet Oncology
Neural Stem Cell Delivery of an Oncolytic Adenovirus in Newly Diagnosed Malignant Glioma

Study investigators examine the safety and activity of NSC-CRAd-S-pk7, an engineered oncolytic adenovirus delivered by neural stem cells, in patients with newly diagnosed high-grade glioma.

The Lancet Oncology
Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study investigators aim to evaluate the antitumour activity and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL.

The Lancet Oncology
Avelumab Alone or in Combination With Chemotherapy versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Study investigators report results of avelumab alone or avelumab plus PLD compared with PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer.

The Lancet Oncology
Chemotherapy De-escalation Using an 18F-FDG-PET-based Pathological Response-Adapted Strategy in Patients With HER2+ Early Breast Cancer

Study investigators assess early metabolic responses to neoadjuvant trastuzumab and pertuzumab using 18F-fluorodeoxyglucose and the possibility of chemotherapy de-escalation using...

The Lancet Oncology
Pralsetinib for RET Fusion-Positive Non-Small-Cell Lung Cancer

Study investigators assess the safety, tolerability, and antitumour activity of pralsetinib, a highly potent, oral, selective RET inhibitor, in patients with RET fusion-positive NSCLC.

The Lancet Oncology
Patient-Reported Outcomes With Atezolizumab Plus Bevacizumab versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma

Study investigators evaluate patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 trial...

The Lancet Oncology
Subscribe to The Lancet Oncology

source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(235, 64, 52)